This webpage is intended for UK-I health care professionals.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events and product complaint should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard for the UK or www.hpra.ie for Ireland. Adverse events and product complaint should also be reported to Angelini Pharma on (UK) +44 2034889643, (IRE) +353 1 584 4671 or UKIReporting@angelinipharma.com
The latest developments for the use of ONTOZRY® in treatment resistant populations of patients with focal-onset seizures is discussed in this series of videos. Experts in their field discuss their experience of using ONTOZRY® in the real world and what this could mean for eligible patients. These panels were led by UK and US experts.
If you were unable to attend any of the events or would like a refresher of the content, you can catch up with the videos below.
We recently invited global experts Prof Gregory Krauss and Prof Bernhard Steinhoff to the UK-I to share their experience with using ONTOZRY® in their clinic. Please watch the video to find out more.
UK18770P | September 2023
Here Professor Gregory Krauss answering a range of questions about his experience with using ONTOZRY® in a clinical setting.
UK17484P | July 2023
Watch our expert panel, assembled from four specialist centres, reflect on one year of real-world experiences with ONTOZRY®.
UK16594 | February 2023
Professor Gregory Krauss presents his real-world experience with ONTOZRY®. Data is presented from the pivotal study paper on ONTOZRY® for which he was lead author.
UK13795P | September 2022
Watch your peers Dr Rhys Thomas and Dr Seán Slaght discuss their experience with ONTOZRY® in clinical practice.
UK11753P | July 2022
Join Dr Rhys Thomas as he answers some key questions about the management of drug-resistant epilepsy at the ABN 2022 Annual Meeting.
UK12966P | September 2022
Consultant Neurologists Dr Rhys Thomas and Dr Barbara Wysota reflect on her ONTOZRY® journey at the ABN 2022 Annual Meeting, from clinical data to real world experience.
UK12967P | September 2022
Harmonia Mentis